Mounjaro weight loss per week: what the evidence actually shows

How the average weekly loss is calculated from SURMOUNT-1

The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight and at least one weight-related condition over 72 weeks. At the 15mg dose, average body-weight reduction was around 20–21%. Spread across 72 weeks, that works out to roughly 0.3% of body weight per week as a crude average, but the actual curve looks nothing like a straight line.

During the first 12 to 24 weeks, when doses are being increased, losses are typically faster. By months seven to twelve, the rate slows as appetite settles into a new baseline. This deceleration is not a sign the medicine is failing; it reflects normal physiology. The NHS tirzepatide page notes that weight loss on this medicine happens gradually alongside lifestyle changes, that framing matters, because week-by-week fixation can lead people to abandon a treatment that is, in fact, working.

Our week-by-week Mounjaro guide breaks down what most people experience at each stage of treatment, from the starter dose right through to maintenance.

Why your weekly number will differ from the trial average

Trial participants follow a strict protocol: supervised dose escalation, regular check-ins, and consistent lifestyle support. Real-world conditions are messier. Tolerability varies, someone who experiences persistent nausea may not titrate as quickly, and a slower dose increase means a slower rate of loss. Starting weight matters too: a person beginning at 130kg may lose 1–1.5kg in an active week early on, while someone starting at 90kg may see 0.5–0.8kg. Both can be proportionally on track.

Metabolic history is another variable. People who have dieted repeatedly may respond more slowly at first due to adaptive changes in their metabolism. Conversely, some people see noticeable change within the first two weeks, before reaching even 5mg. If you have had a week (or several weeks) without movement, that is not necessarily abnormal; the pattern to watch is the trend over four to eight weeks rather than any single point. Stalled loss around week five is one of the most common questions our prescribers hear, and there is usually a physiological explanation.

Dose level and its effect on the weekly rate

The 2.5mg starting dose is there to let your digestive system adapt, not to drive weight loss. Most people see modest or no weight change in the first four weeks, and that is expected. As the dose increases through 5mg, 7.5mg, and beyond, appetite suppression deepens, and the weekly rate typically accelerates before eventually plateauing.

It is also worth knowing that not everyone reaches 15mg. Some people achieve meaningful loss at 10mg or 12.5mg and do not need to go higher. The right maintenance dose is the one your prescriber determines based on your response and tolerability, not the highest one available. A broader look at how Mounjaro produces weight loss explains the dual GIP and GLP-1 mechanism that underpins this effect. For context on how cost relates to dose, our Mounjaro price comparison covers what UK private treatment typically involves.

Practical implications for tracking progress

Weighing yourself daily introduces noise. Hormonal fluctuations, hydration, bowel habits, and muscle gained through activity can all shift the number on the scale by a kilogram or more without reflecting actual fat change. Most clinicians suggest weekly weigh-ins at the same time of day, under the same conditions. Morning, after the bathroom, before breakfast, the pen is probably already in the fridge door next to your other morning medications; make the scale a similar habit.

If you have completed eight weeks on Mounjaro and want to understand your results in that context, our guide to eight-week Mounjaro weight loss sets out what clinical reviewers consider a meaningful response at that stage. NICE's guidance on tirzepatide (TA1026, published December 2024) notes that continuing treatment is reviewed if less than 5% body weight has been lost after six months at the highest tolerated dose, a useful benchmark for both patients and prescribers, and one worth discussing openly at your review. For a broader overview of what tirzepatide is and how it fits into UK weight management, the tirzepatide information page covers the full picture.

If you would like your personal situation reviewed by a clinician, speak to our prescribers, consultations are free and assessed the same day.